CTO, Debulking Devices Poised To Profit From Ancillary Stenting Needs
This article was originally published in The Gray Sheet
Executive Summary
Lumend is developing a second-generation X-35 version of its Frontrunner chronic total occlusion catheter in anticipation of increasingly complex drug-eluting stent procedures
You may also be interested in...
Early-Stage Device Firms Challenge CV Big Five With Alternatives, Adjuncts
Small companies at the research stage are asking investors to support cardiovascular technology projects that would fill treatment gaps left open by surgical interventions and large firms' stent technologies
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.